Skip to content
Breaking
Science

Experimental compound burns fat in mice without major muscle loss

Researchers report early animal results for a compound that raises energy burning. Human safety and effectiveness have not been tested.

University of California, Berkeley in 2015
File photo, 2015: University of California, Berkeley. Photo: Lorenzo Tlacaelel / Wikimedia Commons, CC BY 2.0 (cropped)

Key points

  • Study in mice found TOFA reduced body fat without significant lean muscle loss
  • TOFA increased energy expenditure by up to 18% without more physical activity
  • Mice given TOFA with Ozempic or Wegovy components showed greater benefits
  • Findings were published in Science Advances; human trials have not been done
  • Researchers have set up ReRx Therapeutics to move the work forward

Researchers at UC Berkeley have reported that an experimental compound helped obese mice lose body fat while keeping most of their lean muscle. According to ScienceDaily, the findings were published in the journal Science Advances. The compound, called 5-tetradecyloxy-2-furoic acid, or TOFA, has not been tested for safety or effectiveness in people.

In the mouse experiments, TOFA improved how the animals handled blood sugar and reduced harmful blood fats. It also raised energy use by as much as 18%. The mice did not become more active, and their body temperature did not rise. The team suggests the approach could one day help people with obesity, diabetes and fatty liver disease.

Why researchers chose a different approach

Drugs such as Ozempic, Wegovy, Mounjaro and Zepbound, which belong to a class called GLP-1 drugs, have changed obesity care over the past five years. They help many patients lose weight and manage blood sugar. However, they work mainly by reducing appetite. That can cause nausea, digestive problems, poor nutrition and muscle loss in some patients.

The Berkeley group wanted to test a different route. Instead of asking the body to take in fewer calories, they looked at whether it could burn more energy. Anders Näär, who teaches metabolism science at UC Berkeley and supervised the project, explained the logic in simple terms. He said body weight responds to two factors, intake and energy spending, and that GLP-1 drugs act almost entirely on the first.

How TOFA works in the body

TOFA has two main effects. It blocks part of the lipid-making process, and lipids include cholesterol and triglycerides. It also switches on genes that help cells take up fat and burn it for fuel. The researchers found that TOFA belongs to a group called ACC inhibitors. Earlier drugs in this group reached mid-stage trials, but none has been approved for metabolic disease, partly because many of them raised triglycerides.

According to the study, TOFA also activates two cellular receptors, PPARα and PPARδ, which help control fat metabolism genes. In the mice, TOFA did not raise triglyceride levels. Justin Y. Lee, now a UCSF postdoctoral researcher, carried out the work during doctoral studies at Berkeley and is the study’s first author. He said the compound appears to trigger a coordinated response rather than simply blocking fat production.

Results with existing weight-loss drugs

The team also tested TOFA alongside semaglutide and tirzepatide, the active ingredients in the drugs above. In mice, the combinations produced greater gains in weight loss, blood glucose control, insulin levels and triglyceride levels than either treatment alone. Näär described the interaction as additive or synergistic. He sees TOFA as something to use alongside these medicines rather than in place of them.

The researchers also gave mice two separate compounds, one blocking lipid production and one boosting energy use. That combination worked less well than TOFA alone, which the team says suggests the single molecule’s effect on several processes matters.

What comes next

The researchers stress that all results so far come from animal studies. Scientists still need to learn whether TOFA is safe and useful in people, and whether it could offer advantages over current medicines. To move that work forward, the scientists founded a biotechnology company, ReRx Therapeutics. Backing for the venture came from a campus network that helps life sciences startups, with Nucleate and Berkeley SkyDeck among its programs.

Internal funds at UC Berkeley paid for much of the research. The UCSF Liver Center and the University of Michigan Animal Phenotyping Core also contributed. For now, TOFA remains an early laboratory candidate rather than a treatment.

Frequently asked questions

What is TOFA?

TOFA is the experimental compound 5-tetradecyloxy-2-furoic acid. In mouse studies, it reduced lipid production and activated genes that help the body burn fat.

Is TOFA available to patients?

No. The findings come from animal experiments, and scientists have not yet established whether TOFA is safe or effective in humans.

Could TOFA replace Ozempic or Wegovy?

The researchers do not envision TOFA replacing these drugs. They describe it as complementary, because mice given TOFA with semaglutide or tirzepatide showed greater benefits.

Sources

This article was written with the help of AI from reports by the outlets listed above. See our Editorial Policy. Spotted a mistake? Tell us.

About the author

Ravi Franklin

Founder & Editor

Ravi Franklin is the founder and editor of Peak Journalism. His background is in graphic design and digital content, and he started Peak Journalism to make global news clear and easy to follow.